Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: Results of the Swiss Multicenter Study

被引:10
作者
Langer, Igor
Guller, Ulrich
Koechli, Oss R.
Berclaz, Gilles
Singer, Gad
Schaer, Gabriel
Fehr, Mathias K.
Hess, Thomas
Oertli, Daniel
Bronz, Lucio
Schnarwyler, Beate
Wight, Edward
Uehlinger, Urs
Infanger, Eduard
Burger, Daniel
Zuber, Markus [1 ]
机构
[1] Kantonsspital Olten, Dept Surg, Olten, Switzerland
[2] Univ Basel Hosp, Dept Surg, CH-4031 Basel, Switzerland
[3] Bethanien Clin, Zurich, Switzerland
[4] Univ Hosp Bern, Div Gynecol, CH-3010 Bern, Switzerland
[5] Univ Basel Hosp, Inst Pathol, CH-4031 Basel, Switzerland
[6] Kantonsspital Aarau, Dept Gynecol & Obstet, Aarau, Switzerland
[7] Univ Zurich Hosp, Div Gynecol, CH-8091 Zurich, Switzerland
[8] Kantonsspital Winterthur, Div Gynecol, Winterthur, Switzerland
[9] Osped San Giovanni Bellinzona, Dept Gynecol & Obstet, Bellinzona, Switzerland
[10] Stadspital Triemli, Zurich, Switzerland
[11] Univ Basel Hosp, Div Gynecol, CH-4031 Basel, Switzerland
[12] Kantonsspital Bruderholz, Dept Gynecol & Obstet, Binningen, Switzerland
[13] Kantonales Spital Sursee Wolhusen, Dept Gynecol & Obstet, Wolhusen, Switzerland
关键词
breast cancer; sentinel lymph node; bone marrow micrometastases; correlation; multicenter trial;
D O I
10.1245/s10434-006-9193-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The sentinel lymph node (SLN) status has proven to accurately reflect the remaining axillary lymph nodes and represents the most important prognostic factor. It is unknown whether an association exists between the SLN status and the presence of bone marrow (BM) micrometastases. The objective of the present investigation was to evaluate whether or not such an association exists. Methods: In the present investigation 410 patients with early stage breast cancer (pT1 and pT2 <= 3cm, cN0) were prospectively enrolled between 1/2000 and 12/2003. All patients underwent SLN biopsy and bone marrow aspiration. The histological examination of the SLN consisted of step sectioning, H&E, and immunohistochemistry (Lu-5, CK 22) staining. Cancer cells in the BM were stained with monoclonal antibodies A45-B/B3 against cytokeratin and counted by an automated computerized digital microscope. Results: BM micrometastases were detected in 28.8% (118/410) of all patients. The SLN contained metastases in 32.4% (133/410). Overall 51.2% of the patients (210/410) were SLN negative/BM negative and 12.4% (51/410) SLN positive/BM positive. Of all patients, 16.4% (67/410) were SLN negative/BM positive and 20.0% (82/410) SLN positive/BM negative.There was a statistically significant association between the SLN and BM status, both in unadjusted (Fisher's exact test: P = .004) and multiple logistic regression analysis (P = .007). Conclusions: In the present investigation a significant association was found between a positive SLN status and the presence of BM micrometastases. Nonetheless, the percentage of non-concordance (SLN negative/BM positive and SLN positive/BM negative) was considerable. The prognostic impact of BM micrornetastases in our patient sample remains to be evaluated.
引用
收藏
页码:1896 / 1903
页数:8
相关论文
共 27 条
[1]   Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533
[2]   A pooled analysis of bone marrow micrometastasis in breast cancer [J].
Braun, S ;
Vogl, FD ;
Naume, B ;
Janni, W ;
Osborne, MP ;
Coombes, RC ;
Schlimok, G ;
Diel, IJ ;
Gerber, B ;
Gebauer, G ;
Pierga, JY ;
Marth, C ;
Oruzio, D ;
Wiedswang, G ;
Solomayer, EF ;
Kundt, G ;
Strobl, B ;
Fehm, T ;
Wong, GYC ;
Bliss, J ;
Vincent-Salomon, A ;
Pantel, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) :793-802
[3]   Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy [J].
Braun, S ;
Cevatli, BS ;
Assemi, C ;
Janni, W ;
Kentenich, CRM ;
Schindlbeck, C ;
Rjosk, D ;
Hepp, F .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1468-1475
[4]   Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance [J].
Choesmel, V ;
Pierga, JY ;
Nos, C ;
Vincent-Salomon, A ;
Sigal-Zafrani, B ;
Thiery, JP ;
Blin, N .
BREAST CANCER RESEARCH, 2004, 6 (05) :R556-R569
[5]   A relevant Immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma - Immunomagnetic purification of micrometastases [J].
Choesmel, V ;
Anract, P ;
Hoifodt, H ;
Thiery, JP ;
Blin, N .
CANCER, 2004, 101 (04) :693-703
[6]   PREDICTION OF EARLY RELAPSE IN PATIENTS WITH OPERABLE BREAST-CANCER BY DETECTION OF OCCULT BONE-MARROW MICROMETASTASES [J].
COTE, RJ ;
ROSEN, PP ;
LESSER, ML ;
OLD, LJ ;
OSBORNE, MP .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) :1749-1756
[7]   INCREASED DETECTION OF MAMMARY-CARCINOMA CELLS IN MARROW SMEARS USING ANTISERA TO EPITHELIAL MEMBRANE ANTIGEN [J].
DEARNALEY, DP ;
SLOANE, JP ;
ORMEROD, MG ;
STEELE, K ;
COOMBES, RC ;
CLINK, HMD ;
POWLES, TJ ;
FORD, HT ;
GAZET, JC ;
NEVILLE, AM .
BRITISH JOURNAL OF CANCER, 1981, 44 (01) :85-90
[8]   BREAST-CANCER THERAPY - EXERCISING ALL OUR OPTIONS [J].
DEVITA, VT .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :527-529
[9]   Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal [J].
Diel, IJ ;
Kaufmann, M ;
Costa, SD ;
Holle, R ;
vonMinckwitz, G ;
Solomayer, EF ;
Kaul, S ;
Bastert, G .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (22) :1652-1658
[10]   Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer [J].
Diel, IJ ;
Cote, RJ .
CANCER TREATMENT REVIEWS, 2000, 26 (01) :53-65